Nevertheless, the report does include a short section devoted to this subject, with a focus on the implications of Brexit for the future regulatory environment in the UK. Over the next 5 years, the NHS should undertake 50 collaborative programs in late-stage clinical trials, real-world data collection or the evaluation of medical devices or diagnosticsД«y 2023, the UK should be in the top quartile of comparator countries for speed of adoption and overall uptake of innovative, cost-effective productsД®stablish digital innovation hubs that each provide data across regions of 3-5 million peopleД«uild a migration system that facilitates recruitment of the best talent from around the worldД¬uriously, regulation is not one of the key themes of the life sciences strategy. Over the next 5 years, attract 10 large (ВЈ50-250 million capital investment) and 10 smaller (ВЈ10-50 million capital investment) life sciences manufacturing facilitiesДЄdopt the Accelerated Access ReviewвЂ™s recommendations to create streamlined national market access routes for health technologies Over the next decade, create 4 UK-based companies with a market capitalization of > ВЈ20 billionД«oost investment in manufacture and export of high-value health technologies

Over the next 5 years, increase by 50% the number of clinical trials and raise the proportion of change-of-practice studies and trials with novel methodologiesД®nsure the tax environment supports growth Increase funding for basic science to ensure the UK is in the upper quartile of OECD R&D investmentДЄttract 2,000 new discovery scientists from around the world

Over the next decade, create 2-3 entirely new industries in fields such as genomics, diagnostics, digital health technology, artificial intelligence or healthy ageing. Table 1: Core recommendations and strategic goals in the life sciences strategyД®stablish the Health Advanced Research Program (HARP) to undertake large research infrastructure projects and high-risk вЂњmoonshot programsвЂќ Table 1 summarizes the core recommendations and strategic goals in each of these five areas. The strategy covers five broad themes: the UKвЂ™s science base, growth and infrastructure, collaboration between the NHS and industry, the digitalization of healthcare, and ensuring access to the skills needed to support a flourishing life sciences industry. Sir John Bell, is the product of consultation with a range of stakeholders, including the National Health Service (NHS), the Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA), the devolved administrations in Scotland, Wales, and Northern Ireland, a range of manufacturers, and charities. The eagerly awaited life sciences strategy commissioned by the UK government avowedly вЂњplaces an emphasis on putting the UK in a world-leading position to take advantage of the health technology trends of the next 20 years.вЂќ The report, prepared by eminent geneticist Prof. Following the unveiling of the UKвЂ™ s post-Brexit life sciences strategy, Neil GrubertВ looks at the measures related to market access, a particular challenge in the UK market, and key to its future success in the sector.

Ema shift admin